Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Here’s What Happened

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $25.37, but opened at $23.7101. Chugai Pharmaceutical shares last traded at $23.81, with a volume of 27,262 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. UBS Group upgraded Chugai Pharmaceutical to a “strong-buy” rating in a research report on Tuesday, January 27th. Smbc Nikko Sec. upgraded shares of Chugai Pharmaceutical to a “strong-buy” rating in a report on Wednesday, February 25th. Two equities research analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat, the company has an average rating of “Strong Buy”.

Chugai Pharmaceutical Trading Down 5.9%

The company has a market capitalization of $78.57 billion, a price-to-earnings ratio of 26.52 and a beta of 0.63. The firm’s 50 day simple moving average is $26.61 and its 200-day simple moving average is $27.35.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings data on Friday, April 24th. The company reported $0.22 EPS for the quarter. The firm had revenue of $2.05 billion for the quarter. Chugai Pharmaceutical had a net margin of 34.98% and a return on equity of 22.90%.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.